Abstract
We report the results of the evaluation of a series of imidazole-based compounds against the enzyme 17α- hydroxylase/17,20-lyase (P-45017α). The results show that the compounds were, in general, weak inhibitors of P-45017α in comparison to the standard inhibitor ketoconazole (KTZ) - one was, however, found to be more potent than KTZ.
Keywords: Androgen, Enzyme inhibitor, 17α-hydroxylase, Imidazole, 17,20-lyase, Prostate cancer, Biochemical, 2-imidazol-1-yl-1-phenyl-ethanone, P-45017α, cytochrome, androstenedione (AD), dehydroepiandrosterone (DHEA), progesterone, pregnenolone, NADPH, iron-monooxygen
Letters in Drug Design & Discovery
Title: Synthesis, Biochemical Evaluation and Rationalisation of the Inhibitory Activity of a Range of Derivatives of 2-imidazol-1-yl-1-phenyl-ethanone as Potential Novel Inhibitors of 17α-hydroxylase/17,20-lyase (P-45017α)
Volume: 8 Issue: 6
Author(s): Kruti Shah, Baljeet Jandu, Ammara Abdullah and Sabbir Ahmed
Affiliation:
Keywords: Androgen, Enzyme inhibitor, 17α-hydroxylase, Imidazole, 17,20-lyase, Prostate cancer, Biochemical, 2-imidazol-1-yl-1-phenyl-ethanone, P-45017α, cytochrome, androstenedione (AD), dehydroepiandrosterone (DHEA), progesterone, pregnenolone, NADPH, iron-monooxygen
Abstract: We report the results of the evaluation of a series of imidazole-based compounds against the enzyme 17α- hydroxylase/17,20-lyase (P-45017α). The results show that the compounds were, in general, weak inhibitors of P-45017α in comparison to the standard inhibitor ketoconazole (KTZ) - one was, however, found to be more potent than KTZ.
Export Options
About this article
Cite this article as:
Shah Kruti, Jandu Baljeet, Abdullah Ammara and Ahmed Sabbir, Synthesis, Biochemical Evaluation and Rationalisation of the Inhibitory Activity of a Range of Derivatives of 2-imidazol-1-yl-1-phenyl-ethanone as Potential Novel Inhibitors of 17α-hydroxylase/17,20-lyase (P-45017α), Letters in Drug Design & Discovery 2011; 8 (6) . https://dx.doi.org/10.2174/157018011795906749
DOI https://dx.doi.org/10.2174/157018011795906749 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Prevention with Promising Natural Products: Mechanisms of Action and Molecular Targets
Anti-Cancer Agents in Medicinal Chemistry MRP1-dependent Collateral Sensitivity of Multidrug-resistant Cancer Cells: Identifying Selective Modulators Inducing Cellular Glutathione Depletion
Current Medicinal Chemistry Expression of Estrogen-Regulated Genes During Development in the Mouse Uterus Exposed to Diethylstilbestrol Neonatally
Current Pharmaceutical Design E-Cadherin Upregulation as a Therapeutic Goal in Cancer Treatment
Mini-Reviews in Medicinal Chemistry Benzofuran Small Molecules as Potential Inhibitors of Human Protein Kinases. A Review
Current Pharmaceutical Design Strain-Promoted Cycloadditions for Development of Copper-Free Click Reactions
Current Organic Chemistry Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers
Current Pharmaceutical Design A Mini Review on the Chemistry and Neuroprotective Effects of Silymarin
Current Drug Targets MicroRNA-Mediated Control of Prostate Cancer Metastasis: Implications for the Identification of Novel Biomarkers and Therapeutic Targets
Current Medicinal Chemistry Id-1B, an Alternatively Spliced Isoform of the Inhibitor of Differentiation-1, Impairs Cancer Cell Malignancy Through Inhibition of Proliferation and Angiogenesis
Current Molecular Medicine TRP Channels as A Newly Emerging Non-Voltage-Gated Ca2+ Entry Channel Superfamily
Current Pharmaceutical Design The Quinoline Imidoselenocarbamate EI201 Blocks the AKT/mTOR Pathway and Targets Cancer Stem Cells Leading to a Strong Antitumor Activity
Current Medicinal Chemistry Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals Challenges and Opportunities from Basic Cancer Biology for Nanomedicine for Targeted Drug Delivery
Current Cancer Drug Targets VIP and Drug Design
Current Pharmaceutical Design Multitargeted Molecular Docking Study of Natural-Derived Alkaloids on Breast Cancer Pathway Components
Current Computer-Aided Drug Design Dehydroepiandrosterone and Its Derivatives: Potentially Novel Anti-Proliferative and Chemopreventive Agents
Current Pharmaceutical Design Bioinformatic Screening of Autoimmune Disease Genes and Protein Structure Prediction with FAMS for Drug Discovery
Protein & Peptide Letters Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis
Current Pharmacogenomics and Personalized Medicine TiO<sub>2</sub>~Deoxyribozyme Nanocomposites as Delivery System and Efficient Site-Specific Agents for Cleavage of RNA Targets
Drug Delivery Letters